Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile RB1 del
Therapy REC-617
Indication/Tumor Type Her2-receptor negative breast cancer
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RB1 del Her2-receptor negative breast cancer predicted - sensitive REC-617 Preclinical - Cell culture Actionable In a preclinical study, REC-617 (GTAEXS617) induced cell cycle arrest and apoptosis in CDK4/6 inhibitor-resistant, ESR1-positive, ERBB2 (HER2)-negative breast cancer cells with Rb deletion (Cancer Res (2025) 85 (8_Supplement_1): 366). detail...
PubMed Id Reference Title Details
Abstract 366: CDK7 inhibition as a synthetic lethal strategy in Rb-deficient ER+/HER2- breast cancer and sarcoma cells resistant to CDK4/6 inhibitors Full reference...